{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:13Z","timestamp":1787032873270,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,4]]},"DOI":"10.7759\/cureus.91629","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T03:41:15Z","timestamp":1757043675000},"source":"Crossref","is-referenced-by-count":1,"title":["A Fulminant Case of Refractory Sarcoidosis Triggered by Infliximab-Neutralizing Antibodies"],"prefix":"10.7759","author":[{"given":"Mohamed","family":"Ibraheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahed","family":"Owda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatha","family":"Mallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehad","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre D","year":"2014","unstructured":"Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, M\u00fcller-Quernheim J. Sarcoidosis. Lancet. 2014, 383:1155-67. 10.1016\/S0140-6736(13)60680-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000301","article-title":"Mechanism of granuloma formation in sarcoidosis","volume":"24","author":"Sakthivel P","year":"2017","unstructured":"Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. 2017, 24:59-65. 10.1097\/MOH.0000000000000301","journal-title":"Curr Opin Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30064-X","article-title":"Pulmonary sarcoidosis","volume":"6","author":"Spagnolo P","year":"2018","unstructured":"Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018, 6:389-402. 10.1016\/S2213-2600(18)30064-X","journal-title":"Lancet Respir Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/2040622318790197","article-title":"Epidemiology of sarcoidosis: current findings and future directions","volume":"9","author":"Arkema EV","year":"2018","unstructured":"Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis. 2018, 9:227-40. 10.1177\/2040622318790197","journal-title":"Ther Adv Chronic Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0188","article-title":"Recent advances in sarcoidosis","volume":"139","author":"Morgenthau AS","year":"2011","unstructured":"Morgenthau AS, Iannuzzi MC. Recent advances in sarcoidosis. Chest. 2011, 139:174-82. 10.1378\/chest.10-0188","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"Pariser RJ","year":"2013","unstructured":"Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013, 68:765-73. 10.1016\/j.jaad.2012.10.056","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000328738","article-title":"Long-term treatment with infliximab in patients with sarcoidosis","volume":"83","author":"Hostettler KE","year":"2012","unstructured":"Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-term treatment with infliximab in patients with sarcoidosis. Respiration. 2012, 83:218-24. 10.1159\/000328738","journal-title":"Respiration"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418805732","article-title":"Successful therapy with rituximab in three patients with probable neurosarcoidosis","volume":"11","author":"Zella S","year":"2018","unstructured":"Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Th\u00f6ne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018, 11:10.1177\/1756286418805732","journal-title":"Ther Adv Neurol Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-015-0025-9","article-title":"Rituximab in refractory sarcoidosis: a single centre experience","volume":"13","author":"Cinetto F","year":"2015","unstructured":"Cinetto F, Compagno N, Scarpa R, Malipiero G, Agostini C. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015, 13:10.1186\/s12948-015-0025-9","journal-title":"Clin Mol Allergy"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand V","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, et al.. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017, 31:299-316. 10.1007\/s40259-017-0231-8","journal-title":"BioDrugs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda KS","year":"2013","unstructured":"Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013, 108:40-7. 10.1038\/ajg.2012.363","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.201533","article-title":"The immunogenic part of infliximab is the F(ab\u2032)2, but measuring antibodies to the intact infliximab molecule is more clinically useful","volume":"60","author":"Ben-Horin S","year":"2011","unstructured":"Ben-Horin S, Yavzori M, Katz L, et al.. The immunogenic part of infliximab is the F(ab\u2032)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011, 60:41-8. 10.1136\/gut.2009.201533","journal-title":"Gut"},{"key":"ref13","article-title":"Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients","volume":"64","author":"Scott TF","year":"2007","unstructured":"Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol [Internet. 2007, 64:691-6.","journal-title":"Arch Neurol [Internet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-022-01089-z","article-title":"Neurosarcoidosis: phenotypes, approach to diagnosis and treatment","volume":"24","author":"Gosselin J","year":"2022","unstructured":"Gosselin J, Roy-Hewitson C, Bullis SS, DeWitt JC, Soares BP, Dasari S, Nevares A. Neurosarcoidosis: phenotypes, approach to diagnosis and treatment. Curr Rheumatol Rep. 2022, 24:371-82. 10.1007\/s11926-022-01089-z","journal-title":"Curr Rheumatol Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10793-2","article-title":"Adalimumab for CNS sarcoidosis: single-center experience and literature review","volume":"269","author":"Hutto SK","year":"2022","unstructured":"Hutto SK, Kyle K, Cavanagh JJ, Reda H, Venna N. Adalimumab for CNS sarcoidosis: single-center experience and literature review. J Neurol. 2022, 269:2064-72. 10.1007\/s00415-021-10793-2","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake TR","year":"2009","unstructured":"Radstake TR, Svenson M, Eijsbouts AM, Hoogen FH, Enevold C, van Riel PL, Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009, 68:1739-45. 10.1136\/ard.2008.092833","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02567.x","article-title":"Methotrexate reduces antibody responses to recombinant human \u03b1-galactosidase A therapy in a mouse model of Fabry disease","volume":"137","author":"Garman RD","year":"2004","unstructured":"Garman RD, Munroe K, Richards SM. Methotrexate reduces antibody responses to recombinant human \u03b1-galactosidase A therapy in a mouse model of Fabry disease. Clin Exp Immunol. 2004, 137:496-502. 10.1111\/j.1365-2249.2004.02567.x","journal-title":"Clin Exp Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv027","article-title":"Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease","volume":"9","author":"Colman RJ","year":"2015","unstructured":"Colman RJ, Rubin DT. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015, 9:312-7. 10.1093\/ecco-jcc\/jjv027","journal-title":"J Crohns Colitis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134382","article-title":"The role of low-dose oral methotrexate in increasing anti-TNF drug levels and reducing immunogenicity in IBD","volume":"12","author":"Demase K","year":"2023","unstructured":"Demase K, Monitto CK, Little RD, Sparrow MP. The role of low-dose oral methotrexate in increasing anti-TNF drug levels and reducing immunogenicity in IBD. J Clin Med. 2023, 12:10.3390\/jcm12134382","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis","volume":"29","author":"Thomas SS","year":"2015","unstructured":"Thomas SS, Borazan N, Barroso N, et al.. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015, 29:241-58. 10.1007\/s40259-015-0134-5","journal-title":"BioDrugs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"Crommelin HA","year":"2016","unstructured":"Crommelin HA, van der Burg LM, Vorselaars AD, et al.. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016, 115:72-7. 10.1016\/j.rmed.2016.04.011","journal-title":"Respir Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13010","article-title":"Complete reversion of anti-infliximab immunization by methotrexate combination in a patient with psoriasis","volume":"42","author":"Vincent T","year":"2015","unstructured":"Vincent T, Best M, Plawecki M, Girard C. Complete reversion of anti-infliximab immunization by methotrexate combination in a patient with psoriasis. J Dermatol. 2015, 42:1030-1. 10.1111\/1346-8138.13010","journal-title":"J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389859-a-fulminant-case-of-refractory-sarcoidosis-triggered-by-infliximab-neutralizing-antibodies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T03:41:17Z","timestamp":1757043677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389859-a-fulminant-case-of-refractory-sarcoidosis-triggered-by-infliximab-neutralizing-antibodies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.91629","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}